Gastro News Articles – Gastroenterology Journals

To email this article, enter your own "From Email" address, the recipient's "To Email" address, and click the "Send Email" button. You may send to up to 5 email addresses.
*From Email:
*To Email:
To Email:
To Email:
To Email:
To Email:

A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity
Tol J et al. – For first-line treatment of advanced colorectal cancer (ACC), cetuximab addition to capecitabine, oxaliplatin and bevacizumab is safe and feasible with no observed excessive or unexpected toxicity in the cetuximab treatment arm

Methods

Study to evaluate the effect of adding cetuximab to capecitabine, oxaliplatin and bevacizumab in first-line treatment of ACC (CAIRO2 study)
Randomization of 755 pts to treatment with capecitabine, oxaliplatin and bevacizumab with or without cetuximab
Primary end point: progression-free survival
Toxicity results for first 400 pts reported

Results

Incidence of overall grade 3–4 toxicity was significantly higher in arm B (81%) vs arm A (72%)
Toxicity difference is fully attributed to cetuximab-related skin toxicity
Addition of cetuximab did not increase gastrointestinal toxicity or treatment-related mortality

[more...]

Annals of Oncology

Sponsor

Read a Different Specialty

Allergy/Immunology
Anesthesiology
Cardiology
Dermatology
Drugs
Emergency Medicine
Endocrinology
ENT
Family Medicine

Gastroenterology
Hematology-Oncology
Infectious Disease
Internal Medicine
Nephrology
Neurology
OB/Gyn
Ophthalmology
Orthopedics

Pain
Pediatrics
Practice Management
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology

Dentist
Hospital Administrator
Nurse

Medical Students
Nurse Practitioner
Pharma/Drug Marketer

Pharmacist
Physician Assistants

Article Search

Keyword:

Search:

Published within:

Sort By:
Date Relevance

Sponsor